| Name | Title | Contact Details |
|---|---|---|
Peter Kuper |
Senior Vice President of Finance | Profile |
Adam Walsh |
Chief Financial Officer | Profile |
Celsis International plc is a world leading provider of innovative life science products and laboratory services to the pharmaceutical, biopharmaceutical, and consumer products industries through its three business areas, rapid detection, analytical and
ArQule, Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, & Biotech sector.
Phylagen is a venture-backed microbiome data analytics company that harnesses the vast, unseen world of microbes to improve business performance and make our lives better.
WindMIL Therapeutics is a clinical stage oncology cell therapy company. We are leveraging our proprietary platform to develop a novel class of cell therapies called MILs™ (Marrow Infiltrating Lymphocytes) derived from memory T cells found in the bone marrow.
Cadence Neuroscience is developing a next generation implantable device therapy for epilepsy. The therapy, pioneered by researchers at Mayo Clinic over the past decade, uses advanced methods to provide individualized treatment for each patient. Our core technology includes a specialized neuromodulation platform that enables these methods. Cadence is currently engaged in the engineering and testing of the platform, and preparing for additional clinical evaluations.